Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo.
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsBeyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint RegulatorsImmune checkpoint blockade: a common denominator approach to cancer therapyImmune Checkpoint in Glioblastoma: Promising and ChallengingPoxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.Emerging immune checkpoints for cancer therapy.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.Epigenetic Modification Mediates the Increase of LAG-3+ T Cells in Chronic Osteomyelitis.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.LAG3 (CD223) as a cancer immunotherapy target.Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory InfectionImmune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression.In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis.Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy.Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.Not All Immune Checkpoints Are Created EqualImmuno-Oncology: Emerging Targets and Combination Therapies
P2860
Q26745842-DA83441E-BD4F-436F-ACE6-8FEDFA824A7AQ26782799-BB118821-460B-430A-9DF7-929C505F5011Q28083981-EC96F278-62F4-45C4-88EC-837020417579Q33650058-77900AB1-1B2C-4C70-9312-39B20BC08081Q35934137-7C503EEA-103A-4A45-807F-46297EEC4A7DQ38584979-13D2B338-E148-4A77-B8BA-ACFFCBDD22EBQ38899873-38722CA3-B0B8-45B4-B979-52A4AAA2340DQ39043404-FC70154C-F16C-4A6E-A1B5-08AE0269C173Q39061240-2EB81E32-9D52-4D6B-8A83-DE00D08FB380Q39078341-0994331C-6294-4FE8-A80F-6CDF0A919ADFQ39160974-DB128AD4-6501-4021-A018-775E6CD6707EQ39262779-C14809F5-FE30-426B-B8DF-05ADA887543EQ40646507-0150A6F5-5CCE-42E7-84E0-E57632EB9FCAQ47221330-C122BD77-E993-4CAE-850B-5ECB64D2FEC7Q48098105-41E9E416-BA36-47AA-AB81-527F1E461CAFQ52579155-7C9F1728-C21F-444F-801B-7E5CA93D7580Q54218762-436AF201-41CD-4432-A991-689C8CF1A873Q56889626-7D8F9DAF-9756-4DF4-9BDD-4F2B2E76609CQ56889817-937E57F2-EF2B-4EC4-B538-8FB344B14474
P2860
Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Lymphocyte Activation Gene 3 ( ...... ells to be suppressed in vivo.
@en
Lymphocyte Activation Gene 3
@nl
type
label
Lymphocyte Activation Gene 3 ( ...... ells to be suppressed in vivo.
@en
Lymphocyte Activation Gene 3
@nl
prefLabel
Lymphocyte Activation Gene 3 ( ...... ells to be suppressed in vivo.
@en
Lymphocyte Activation Gene 3
@nl
P2093
P2860
P1433
P1476
Lymphocyte Activation Gene 3 ( ...... ells to be suppressed in vivo.
@en
P2093
Charles G Drake
Christina M Kochel
Christopher J Nirschl
Christopher M Jackson
Jimmy Elias
Nicholas M Durham
Robert A Anders
P2860
P304
P356
10.1371/JOURNAL.PONE.0109080
P407
P577
2014-11-05T00:00:00Z